Biobetters 市場、機會、成長動力、產業趨勢分析與預測，2024-2032 年

2023 年，全球 Biobetters 市場估值為 528 億美元，由於癌症、糖尿病和自體免疫疾病等慢性疾病的盛行率不斷上升，2024 年至 2032 年期間複合年成長率將達到 8.3%。隨著這些病症變得越來越普遍，對可提高療效並改善患者預後的先進治療的需求不斷增加。生物技術的創新，包括蛋白質工程和藥物傳遞系統的進步，使得能夠開發出與現有生物製劑相比具有更優越治療效果的生物改良劑。不斷成長的醫療需求和技術進步的結合將推動市場擴張。

生物改良劑產業根據藥物類別、應用、給藥途徑、配銷通路和地區進行分類。

憑藉其巨大的治療潛力和廣泛的應用，單株抗體 Biobetter 細分市場到 2023 年將獲得 385 億美元的收入。單株抗體對於治療各種疾病至關重要，包括癌症和自體免疫疾病。這些抗體的改進版本提供了更高的功效、更長的半衰期和更少的副作用，從而推動了它們的需求。隨著市場不斷擴大，重點開發更有效、更有針對性的單株抗體療法將鞏固該領域的主導地位。

2023 年，醫院藥局部門的銷售額為 252 億美元，主要是因為它們在管理複雜的生物治療方面發揮核心作用。醫院藥局配備齊全，可滿足單株抗體和其他先進療法等生物改良劑的專門儲存和處理要求。此外，這些設施對於管理患者特定劑量和為藥物管理提供專家支援至關重要。隨著生物改良劑使用的成長，醫院藥房將繼續成為關鍵部分，以支持這些先進治療方法的分配和最佳化使用。

由於其先進的醫療基礎設施、慢性病的高盛行率以及對生物技術創新的高度重視，到 2032 年，北美生物改良劑市場將產生 441 億美元的收入。該地區成熟的製藥業和充足的研發投資有助於生物改良劑的開發和採用。此外，有利的監管環境和高醫療保健支出進一步推動市場成長。隨著北美在技術進步和治療創新方面繼續領先，它仍然是生物改良劑行業的關鍵貢獻者。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 增強治療效果並減少副作用
    • 慢性病盛行率上升
    • 不斷增加對生物改良劑研發的投資
  • 產業陷阱與挑戰
    • 開發成本高
    • 嚴格的監管場景
• 成長潛力分析
• 監管環境
• 技術景觀
  • 核心技術
  • 鄰近技術
• 未來市場趨勢
• 差距分析
• 波特的分析
• 杵分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

• 主要趨勢
• 促紅血球生成素生物改善劑
• 胰島素生物改善劑
• G-CSF生物改良劑
• 單株抗體生物改良劑
• 抗血友病因子
• 其他藥物類別

第 6 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 癌症
• 糖尿病
• 腎臟疾病
• 神經退化性疾病
• 遺傳性疾病
• 其他應用

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

• 主要趨勢
• 皮下
• 靜脈
• 其他給藥途徑

第 8 章：市場估計與預測：按配銷通路，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Biogen Inc.
• Bristol-Myers Squibb Company
• Celltrion Inc.
• Eli Lilly And Company
• F. Hoffmann-La Roche Ltd.
• GSK plc
• Kiniksa Pharmaceuticals, Ltd.
• Merck and Co., Inc.
• Novo Nordisk A/S
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Teva Pharmaceutical Industries Limited

The Global Biobetters Market was valued at USD 52.8 billion in 2023 and will grow at an 8.3% CAGR between 2024 and 2032, attributed to the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders. As these conditions become more common, there is an increased demand for advanced treatments that offer enhanced efficacy and improved patient outcomes. Innovations in biotechnology, including advancements in protein engineering and drug delivery systems, enable the development of biobetters with superior therapeutic profiles compared to existing biologics. This combination of growing medical needs and technological progress will propel the market expansion.

The biobetters industry is segregated on the basis of drug class, application, route of administration, distribution channel, and region.

The monoclonal antibodies biobetters segment garnered USD 38.5 billion in 2023, propelled by their significant therapeutic potential and widespread use. Monoclonal antibodies are crucial in treating various diseases, including cancers and autoimmune disorders. Improved versions of these antibodies offer enhanced efficacy, a longer half-life, and reduced side effects, which drive their demand. As the market continues to expand, the focus on developing more effective and targeted monoclonal antibody therapies will reinforce this segment's dominance.

The hospital pharmacies segment held USD 25.2 billion in 2023, primarily due to their central role in administering complex biological treatments. Hospital pharmacies are equipped to handle the specialized storage and handling requirements of biobetters, such as monoclonal antibodies and other advanced therapies. Additionally, these facilities are crucial for managing patient-specific dosing and providing expert support for drug administration. As the use of biobetters grows, hospital pharmacies will continue to be a key segment, supporting the distribution and optimal use of these advanced treatments.

North America biobetters market will generate USD 44.1 billion by 2032 due to its advanced healthcare infrastructure, high prevalence of chronic diseases, and strong focus on biotechnology innovation. The region's well-established pharmaceutical industry and ample investment in research and development contribute to the development and adoption of biobetters. Besides, favorable regulatory environments and high healthcare spending further drive market growth. As North America continues to lead in technological advancements and therapeutic innovations, it remains a key contributor to the biobetters industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Enhanced therapeutic effectiveness and reduced side effects
    • 3.2.1.2 Rising prevalence of chronic disease
    • 3.2.1.3 Growing investment in research and development of biobetters
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development costs
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTLE analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Erythropoietin biobetters
• 5.3 Insulin biobetters
• 5.4 G-CSF biobetters
• 5.5 Monoclonal antibodies biobetters
• 5.6 Antihemophilic factor
• 5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cancer
• 6.3 Diabetes
• 6.4 Renal disease
• 6.5 Neurodegenerative disease
• 6.6 Genetic disorders
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Subcutaneous
• 7.3 Intravenous
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 AstraZeneca PLC
• 10.4 Biogen Inc.
• 10.5 Bristol-Myers Squibb Company
• 10.6 Celltrion Inc.
• 10.7 Eli Lilly And Company
• 10.8 F. Hoffmann-La Roche Ltd.
• 10.9 GSK plc
• 10.10 Kiniksa Pharmaceuticals, Ltd.
• 10.11 Merck and Co., Inc.
• 10.12 Novo Nordisk A/S
• 10.13 Regeneron Pharmaceuticals, Inc.
• 10.14 Sanofi
• 10.15 Teva Pharmaceutical Industries Limited